- Allarity warned of pending SEC charges over FDA meeting conduct🔍
- SEC Hits Allarity With Wells Notice🔍
- Allarity Therapeutics🔍
- Edelson Lechtzin LLP Reminds Allarity Therapeutics🔍
- The Law Offices of Frank R. Cruz Reminds Investors of Looming ...🔍
- Annalee Armstrong🔍
- Allarity Warns Of SEC Suit Over Cancer Drug Statements🔍
- Registration No. 333🔍
Allarity warned of pending SEC charges over FDA meeting conduct
Allarity warned of pending SEC charges over FDA meeting conduct
Allarity has received notice that an SEC enforcement action is pending regarding FDA meetings surrounding a new drug application for ...
SEC Hits Allarity With Wells Notice, Flags Alleged Violations in FDA ...
The US Securities and Exchange Commission has slapped Allarity Therapeutics with a Wells Notice over alleged violations of federal securities law.
Allarity Therapeutics - Fierce Biotech
Prothena promotes one exec while another leaves—Chutes & Ladders · Allarity warned of pending SEC charges over FDA meeting conduct.
Edelson Lechtzin LLP Reminds Allarity Therapeutics, Inc. (NASDAQ
Edelson Lechtzin LLP, a leading class action law firm, announces the recent filing of a securities fraud class action on behalf of ...
The Law Offices of Frank R. Cruz Reminds Investors of Looming ...
Cruz reminds investors of the upcoming November 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of ...
Annalee Armstrong | Fierce Healthcare
Allarity warned of pending SEC charges over FDA meeting conduct image-icon ... Allarity has received notice that an SEC enforcement action is pending regarding ...
On May 20, 2021, we entered a Plan of Reorganization and Asset Purchase Agreement (the “Recapitalization Share Exchange”), between us, Allarity Acquisition ...
Allarity Warns Of SEC Suit Over Cancer Drug Statements - Law360
Clinical stage pharmaceutical company Allarity Therapeutics informed investors Monday that the U.S. Securities and Exchange Commission is ...
Registration No. 333 - SEC.gov
The pre-funded warrants and common warrants are immediately separable and will be issued separately in this offering. For each pre-funded warrant we sell, the ...
SEC Interest in FDA-Related Disclosures by Life Sciences ...
The CEO is also facing a forthcoming criminal trial. We have also seen press reports of a Wells Notice issued by the SEC to Allarity ...
Registration No. 333-270514 - SEC.gov
As a result, the Company's securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of such ...
In the event our shares of Common Stock are no longer listed for trading on Nasdaq, our trading volume and share price may decrease and you may have a difficult ...
... Charges, 12/19/2022. 9, 2016-1224, The Verge, EMAILS, LETTERS BETWEEN FDA AND ... MEETING REFERENCE IN EIR 05/01/2013 - 04/29/2014, Withdrawn Closed w/o ...
Allarity Therapeutics, Inc. Class Action Alert: Wolf - GlobeNewswire
On February 6, 2023, Allarity disclosed that it had received a letter to produce documents from the United States Securities and Commission (“ ...
This prospectus relates to the resale or disposition of up to 4,877,778 shares of common stock, par value $0.0001 per share, of Allarity Therapeutics, Inc. (“we ...
IPCalculus Information Services Pvt. Ltd. on LinkedIn: Delhi HC bars ...
Allarity warned of pending SEC enforcement action over FDA meeting conduct ... Oracle wins $58.5 mln in attorneys' fees in Rimini copyright case.
... conduct clinical trials on our therapeutic candidates or the FDA ... In June 2019, the FDA had provided feedback on our pending Investigational ...
Allarity Therapeutics, Inc. (Form: S-4, Received - EDGAR Online
On May 20, 2021, Allarity Therapeutics, Inc. (“Allarity Delaware”), a Delaware corporation and a direct and wholly owned subsidiary of Allarity ...
united states securities and exchange commission - form 10-k
According to the FDA's fiscal year 2022 fee schedule, effective through ... fees on any issued patent and pending patent application must ...
allarity therapeutics, inc. - SEC.gov
On May 20, 2021, Allarity Therapeutics, Inc. (“Allarity Delaware”), a Delaware corporation and a direct and wholly owned subsidiary of Allarity Therapeutics A/S ...